K-Ras mutations occur as an early event in about 50% of CRC cases, resulting in constitutive activation of the RAS-RAF-MEK-ERK pathway, and a subsequent resistance to anti-EGFR therapy by monoclonal antibodies Cetuximab and Panitumumab. This evidence concerns the gene EGFR and colorectal carcinoma.